Maynard Um
-
-
-
-
-
-
-
Novartis halts ALS drug development after mid-stage trial fails
-
-
-
-
-
-
-
CLSA Reiterates Outperform (2) Rating on Novartis (NOVN:SW) (NVS)
-
-
-
-
-
-
-
JPMorgan Reiterates Overweight Rating on Novartis (NOVN:SW) (NVS)
-
-
-
-
-
-
-
Novartis drug shows efficacy in chronic urticaria trial
-
-
-
-
-
-
-
Novartis breaks ground on Texas radioligand therapy manufacturing site
-
-
-
-
-
-
-
Novartis to acquire biotech Excellergy for up to $2 billion
-
-
-
-
-
-
-
Novartis shareholders approve 5.7% dividend increase at annual meeting
-
470,296 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


